JP2016116520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016116520A5 JP2016116520A5 JP2015252875A JP2015252875A JP2016116520A5 JP 2016116520 A5 JP2016116520 A5 JP 2016116520A5 JP 2015252875 A JP2015252875 A JP 2015252875A JP 2015252875 A JP2015252875 A JP 2015252875A JP 2016116520 A5 JP2016116520 A5 JP 2016116520A5
- Authority
- JP
- Japan
- Prior art keywords
- antisense oligonucleotide
- nucleotides
- seq
- oligonucleotide
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76295406P | 2006-01-26 | 2006-01-26 | |
| US60/762,954 | 2006-01-26 | ||
| US83629006P | 2006-08-07 | 2006-08-07 | |
| US60/836,290 | 2006-08-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013115737A Division JP5916660B2 (ja) | 2006-01-26 | 2013-05-31 | ハンチンチン対する、組成物及びその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018061748A Division JP2018117635A (ja) | 2006-01-26 | 2018-03-28 | ハンチンチン対する、組成物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016116520A JP2016116520A (ja) | 2016-06-30 |
| JP2016116520A5 true JP2016116520A5 (enExample) | 2016-08-12 |
| JP6395058B2 JP6395058B2 (ja) | 2018-09-26 |
Family
ID=38164262
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008552447A Active JP5425474B2 (ja) | 2006-01-26 | 2007-01-26 | ハンチンチン対する、組成物及びその使用 |
| JP2013115737A Active JP5916660B2 (ja) | 2006-01-26 | 2013-05-31 | ハンチンチン対する、組成物及びその使用 |
| JP2015252875A Active JP6395058B2 (ja) | 2006-01-26 | 2015-12-25 | ハンチンチン対する、組成物及びその使用 |
| JP2018061748A Pending JP2018117635A (ja) | 2006-01-26 | 2018-03-28 | ハンチンチン対する、組成物及びその使用 |
| JP2020023793A Pending JP2020096624A (ja) | 2006-01-26 | 2020-02-14 | ハンチンチン対する、組成物及びその使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008552447A Active JP5425474B2 (ja) | 2006-01-26 | 2007-01-26 | ハンチンチン対する、組成物及びその使用 |
| JP2013115737A Active JP5916660B2 (ja) | 2006-01-26 | 2013-05-31 | ハンチンチン対する、組成物及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018061748A Pending JP2018117635A (ja) | 2006-01-26 | 2018-03-28 | ハンチンチン対する、組成物及びその使用 |
| JP2020023793A Pending JP2020096624A (ja) | 2006-01-26 | 2020-02-14 | ハンチンチン対する、組成物及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (14) | US7951934B2 (enExample) |
| EP (5) | EP3210633B1 (enExample) |
| JP (5) | JP5425474B2 (enExample) |
| AU (4) | AU2007210038B2 (enExample) |
| CA (1) | CA2638908C (enExample) |
| DK (1) | DK2161038T3 (enExample) |
| ES (2) | ES2453380T3 (enExample) |
| PL (2) | PL2161038T3 (enExample) |
| PT (1) | PT2161038E (enExample) |
| SI (1) | SI2161038T1 (enExample) |
| WO (2) | WO2007089611A2 (enExample) |
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007089611A2 (en) | 2006-01-26 | 2007-08-09 | Isis Pharmaceuticals Inc. | Compositions and their uses directed to huntingtin |
| EP2049664B1 (en) | 2006-08-11 | 2011-09-14 | Prosensa Technologies B.V. | Single stranded oligonucleotides complementary to repetitive elements for treating DNA repeat instability associated genetic disorders |
| ES2377327T5 (es) | 2006-10-18 | 2020-04-28 | Ionis Pharmaceuticals Inc | Compuestos antisentido |
| WO2008134646A2 (en) * | 2007-04-26 | 2008-11-06 | University Of Iowa Research Foundation | Rna interference suppression of neurodegenerative diseases and methods of use thereof |
| AU2008260103B2 (en) | 2007-05-31 | 2014-04-03 | University Of Iowa Research Foundation | Reduction of off-target RNA interference toxicity |
| CA2693742A1 (en) | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
| USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
| PT2203173E (pt) | 2007-10-26 | 2016-03-15 | Academisch Ziekenhuis Leiden | Resumo |
| CN101980726A (zh) | 2008-02-08 | 2011-02-23 | 普罗森那控股公司 | 治疗与dna重复不稳定性相关的遗传病症的方法和装置 |
| US8679750B2 (en) | 2008-05-09 | 2014-03-25 | The University Of British Columbia | Methods and compositions for the treatment of Huntington'S disease |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| AU2009276763B2 (en) | 2008-07-29 | 2015-07-16 | The Board Of Regents Of The University Of Texas Sytem | Selective inhibition of polyglutamine protein expression |
| EP2323667A4 (en) * | 2008-08-07 | 2012-07-25 | Isis Pharmaceuticals Inc | MODULATION OF TRANSTHYRETIN EXPRESSION BY TREATMENT OF CNS DISEASES |
| US8334372B2 (en) * | 2008-10-15 | 2012-12-18 | Isis Pharmaceuticals, Inc. | Modulation of factor 11 expression |
| WO2010064146A2 (en) | 2008-12-02 | 2010-06-10 | Chiralgen, Ltd. | Method for the synthesis of phosphorus atom modified nucleic acids |
| ES2593836T3 (es) | 2009-04-24 | 2016-12-13 | Biomarin Technologies B.V. | Oligonucleótido que comprende una inosina para tratar la DMD |
| EP2432881B1 (en) * | 2009-05-18 | 2017-11-15 | CuRNA, Inc. | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor |
| NZ597071A (en) * | 2009-06-17 | 2014-05-30 | Isis Pharmaceuticals Inc | Compositions and methods for modulation of smn2 splicing in a subject |
| CA2767253A1 (en) | 2009-07-06 | 2011-01-13 | Ontorii, Inc. | Novel nucleic acid prodrugs and methods of use thereof |
| EP3626823A1 (en) | 2009-09-11 | 2020-03-25 | Ionis Pharmaceuticals, Inc. | Modulation of huntingtin expression |
| WO2011078672A1 (en) | 2009-12-24 | 2011-06-30 | Prosensa Technologies B.V. | Molecule for treating an inflammatory disorder |
| EP2534262B1 (en) * | 2010-02-08 | 2016-12-14 | Ionis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| AU2011213562B2 (en) | 2010-02-08 | 2016-07-07 | Ionis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| US20130059902A1 (en) * | 2010-02-08 | 2013-03-07 | Isis Pharmaceuticals, Inc. | Methods and compositions useful in treatment of diseases or conditions related to repeat expansion |
| WO2011097614A1 (en) * | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Mehods and compositions useful in diseases or conditions related to repeat expansion |
| EP2380595A1 (en) | 2010-04-19 | 2011-10-26 | Nlife Therapeutics S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
| WO2011139917A1 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Modulation of transthyretin expression |
| DK3031920T3 (da) | 2010-07-19 | 2019-10-14 | Ionis Pharmaceuticals Inc | Modulation af dystrofi myotonica-protein kinase (dmpk) ekspression |
| DK2601294T3 (en) | 2010-08-05 | 2019-02-18 | Academisch Ziekenhuis Leiden | ANTISENSE OLIGONUCLEOTIDE CALCULATED FOR THE REMOVAL OF PROTEOLYTIC DIVISION PLACES FROM PROTEINS |
| WO2012039448A1 (ja) | 2010-09-24 | 2012-03-29 | 株式会社キラルジェン | 不斉補助基 |
| JP6126009B2 (ja) * | 2010-11-17 | 2017-05-10 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | α−シヌクレイン発現の調節 |
| EP3067421B1 (en) | 2011-02-08 | 2018-10-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| US9181544B2 (en) | 2011-02-12 | 2015-11-10 | University Of Iowa Research Foundation | Therapeutic compounds |
| CR20190207A (es) | 2011-04-21 | 2019-06-26 | Ionis Pharmaceuticals Inc | MODULACIÓN DE LA EXPRESIÓN DEL VIRUS DE LA HEPATITIS B (VHB) (Divisional 2013-0551) |
| WO2012144906A1 (en) | 2011-04-22 | 2012-10-26 | Prosensa Technologies B.V. | New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (dm1) |
| CN103796657B (zh) | 2011-07-19 | 2017-07-11 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| WO2013022966A1 (en) * | 2011-08-11 | 2013-02-14 | Isis Pharmaceuticals, Inc. | Linkage modified gapped oligomeric compounds and uses thereof |
| US9976138B2 (en) | 2011-08-29 | 2018-05-22 | Ionis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
| CA2862628C (en) | 2012-01-27 | 2021-08-24 | Prosensa Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
| US9914922B2 (en) | 2012-04-20 | 2018-03-13 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| PL2841578T3 (pl) | 2012-04-23 | 2017-12-29 | Biomarin Technologies B.V. | Oligonukleotydy modulujące RNA o ulepszonych właściwościach do leczenia zaburzeń nerwowo-mięśniowych |
| CA2879066C (en) | 2012-07-13 | 2019-08-13 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
| JP6453212B2 (ja) | 2012-07-13 | 2019-01-16 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | キラル制御 |
| WO2014010250A1 (en) | 2012-07-13 | 2014-01-16 | Chiralgen, Ltd. | Asymmetric auxiliary group |
| WO2014059353A2 (en) | 2012-10-11 | 2014-04-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and uses thereof |
| EP2906256B1 (en) | 2012-10-12 | 2018-08-22 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| HK1212597A1 (zh) | 2012-10-15 | 2016-06-17 | Isis Pharmaceuticals, Inc. | 用於調節c90rf72表達的組合物 |
| WO2014062736A1 (en) | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Methods for monitoring c9orf72 expression |
| RU2670614C9 (ru) * | 2013-05-01 | 2018-11-23 | Ионис Фармасьютикалз, Инк. | Композиции и способы модулирования экспрессии hbv и ttr |
| GB201308259D0 (en) * | 2013-05-08 | 2013-06-12 | Iles Raymond K | Cancer diagnosis and monitoring |
| WO2015017675A2 (en) | 2013-07-31 | 2015-02-05 | Isis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
| TW201536329A (zh) | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| SG11201602597YA (en) | 2013-10-11 | 2016-05-30 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
| JPWO2015108046A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
| WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| KR20230152178A (ko) | 2014-01-16 | 2023-11-02 | 웨이브 라이프 사이언시스 리미티드 | 키랄 디자인 |
| US9523093B2 (en) | 2014-05-20 | 2016-12-20 | University Of Iowa Research Foundation | Huntington's disease therapeutic compounds |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| BR112017004056A2 (pt) | 2014-09-12 | 2017-12-05 | Biogen Ma Inc | composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo |
| AU2015327836B2 (en) | 2014-10-03 | 2021-07-01 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| EP3230445B1 (en) * | 2014-12-12 | 2024-01-24 | Tod M. Woolf | Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides |
| GB201504124D0 (en) | 2015-03-11 | 2015-04-22 | Proqr Therapeutics B V | Oligonucleotides |
| SG11201708468YA (en) | 2015-04-16 | 2017-11-29 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
| MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| EP3359685A1 (en) | 2015-10-09 | 2018-08-15 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
| CA3004713A1 (en) * | 2015-10-09 | 2017-04-13 | The Children's Hospital Of Philadelphia | Compositions and methods for treating huntington's disease and related disorders |
| WO2017079291A1 (en) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating c90rf72 |
| CN113750101A (zh) | 2015-12-10 | 2021-12-07 | Ptc医疗公司 | 用于治疗亨廷顿病的方法 |
| ES2882500T3 (es) | 2015-12-14 | 2021-12-02 | Cold Spring Harbor Laboratory | Oligómeros antisentido para el tratamiento del síndrome de Dravet |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| MA45270A (fr) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| JP2019535839A (ja) | 2016-11-29 | 2019-12-12 | ピュアテック ヘルス エルエルシー | 治療剤の送達のためのエクソソーム |
| US11407753B2 (en) | 2017-06-05 | 2022-08-09 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| CA3067591A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
| EP3645121B8 (en) | 2017-06-28 | 2025-06-18 | PTC Therapeutics, Inc. | Methods for treating huntington's disease |
| RS65031B1 (sr) | 2017-08-25 | 2024-02-29 | Stoke Therapeutics Inc | Antisens oligomeri za lečenje stanja i bolesti |
| TWI809004B (zh) | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | 用於降低snca表現之化合物及方法 |
| EP3710087A4 (en) | 2017-11-15 | 2021-09-08 | Alcyone Lifesciences, Inc. | THERAPY-SPECIFIC PRE-PROGRAMMED AUTOMATIC INJECTION DEVICE |
| EP3724214A4 (en) | 2017-12-15 | 2021-09-01 | The Broad Institute Inc. | SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING |
| JP7547201B2 (ja) | 2018-01-12 | 2024-09-09 | ブリストル－マイヤーズ スクイブ カンパニー | アルファ－シヌクレインを標的とするアンチセンスオリゴヌクレオチドおよびその使用 |
| PE20201501A1 (es) | 2018-01-12 | 2020-12-29 | Bristol Myers Squibb Co | Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos |
| KR20210005559A (ko) | 2018-03-27 | 2021-01-14 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
| JP2021523227A (ja) | 2018-05-04 | 2021-09-02 | ストーク セラピューティクス，インク． | コレステリルエステル蓄積症の処置のための方法及び組成物 |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| WO2020005877A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| LT3814357T (lt) | 2018-06-27 | 2024-06-25 | Ptc Therapeutics, Inc. | Heterocikliniai ir heteroarilų junginiai, skirti hantingtono ligos gydymui |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| WO2020117705A1 (en) * | 2018-12-03 | 2020-06-11 | Triplet Therapeutics, Inc. | Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh1 activity |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| GB2601617B (en) | 2019-03-19 | 2024-02-21 | Broad Inst Inc | Methods and compositions for editing nucleotide sequences |
| EP3956349A1 (en) | 2019-04-17 | 2022-02-23 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2021072328A1 (en) | 2019-10-10 | 2021-04-15 | The Broad Institute, Inc. | Methods and compositions for prime editing rna |
| US20240216369A1 (en) | 2019-11-01 | 2024-07-04 | Novartis Ag | The use of a splicing modulator for a treatment slowing progression of huntington's disease |
| US20230340470A1 (en) * | 2019-12-20 | 2023-10-26 | Asklepios Biopharmaceutical, Inc. | Methods for treating huntington's disease |
| BR112022016370A2 (pt) * | 2020-02-21 | 2022-10-04 | Ionis Pharmaceuticals Inc | Métodos para reduzir a expressão de htt |
| EP4146804A1 (en) | 2020-05-08 | 2023-03-15 | The Broad Institute Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| AU2021270720A1 (en) | 2020-05-11 | 2022-12-08 | Stoke Therapeutics, Inc. | OPA1 antisense oligomers for treatment of conditions and diseases |
| US11408000B2 (en) | 2020-06-03 | 2022-08-09 | Triplet Therapeutics, Inc. | Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity |
| TW202304446A (zh) | 2021-03-29 | 2023-02-01 | 瑞士商諾華公司 | 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途 |
| CN117203336A (zh) | 2021-03-29 | 2023-12-08 | 阿尔尼拉姆医药品有限公司 | 亨廷顿蛋白(HTT)iRNA药剂组合物以及其使用方法 |
| US11833221B2 (en) | 2021-09-01 | 2023-12-05 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds for reducing DMPK expression |
| TW202334418A (zh) * | 2021-10-29 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | 杭丁頓（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法 |
| JP2025508959A (ja) * | 2022-03-02 | 2025-04-10 | タケダ ファーマシューティカルズ ユーエスエー インコーポレイテッド | Ｍｓｈ３活性と関連するヌクレオチドリピート伸長障害の治療方法 |
| WO2024077267A1 (en) * | 2022-10-07 | 2024-04-11 | The Broad Institute, Inc. | Prime editing methods and compositions for treating triplet repeat disorders |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US667046A (en) | 1899-06-23 | 1901-01-29 | John W Weeks | Pressure-reducing valve. |
| US2526893A (en) | 1946-08-28 | 1950-10-24 | Cutler Hammer Inc | Dynamic braking control |
| US4426330A (en) | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
| FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| DE3788914T2 (de) | 1986-09-08 | 1994-08-25 | Ajinomoto Kk | Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere. |
| US5403711A (en) | 1987-11-30 | 1995-04-04 | University Of Iowa Research Foundation | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved |
| ATE151467T1 (de) | 1987-11-30 | 1997-04-15 | Univ Iowa Res Found | Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5227170A (en) | 1989-06-22 | 1993-07-13 | Vestar, Inc. | Encapsulation process |
| US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5356633A (en) | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
| US5527528A (en) | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
| EP0497875B1 (en) | 1989-10-24 | 2000-03-22 | Isis Pharmaceuticals, Inc. | 2' modified oligonucleotides |
| US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| US5469854A (en) | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
| US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
| US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
| US5623065A (en) | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
| US5220007A (en) | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
| US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
| ATE167523T1 (de) | 1990-05-11 | 1998-07-15 | Microprobe Corp | Teststreifen zum eintauchen für nukleinsäure- hybridisierungsassays und verfahren zur kovalenten immobilisierung von oligonucleotiden |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| JP3220180B2 (ja) | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | 薬剤含有タンパク質結合リポソーム |
| NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| US5521291A (en) | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
| DE59208572D1 (de) | 1991-10-17 | 1997-07-10 | Ciba Geigy Ag | Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte |
| NZ244820A (en) * | 1991-10-25 | 1994-01-26 | Isis Pharmaceuticals Inc | Oligonucleotide inhibitor of epstein-barr virus. |
| US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
| US5700922A (en) * | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
| FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
| FR2692265B1 (fr) | 1992-05-25 | 1996-11-08 | Centre Nat Rech Scient | Composes biologiquement actifs de type phosphotriesters. |
| EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
| US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
| US6180403B1 (en) * | 1999-10-28 | 2001-01-30 | Isis Pharmaceuticals Inc. | Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression |
| US5583020A (en) | 1992-11-24 | 1996-12-10 | Ribozyme Pharmaceuticals, Inc. | Permeability enhancers for negatively charged polynucleotides |
| JP3351476B2 (ja) | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | リン脂質誘導体及びそれを含有するリポソーム |
| US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
| ATE155467T1 (de) | 1993-03-30 | 1997-08-15 | Sanofi Sa | Acyclische nucleosid analoge und sie enthaltende oligonucleotidsequenzen |
| DE4311944A1 (de) | 1993-04-10 | 1994-10-13 | Degussa | Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen |
| US5462854A (en) | 1993-04-19 | 1995-10-31 | Beckman Instruments, Inc. | Inverse linkage oligonucleotides for chemical and enzymatic processes |
| FR2705099B1 (fr) | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Oligonucléotides phosphorothioates triesters et procédé de préparation. |
| US5534259A (en) | 1993-07-08 | 1996-07-09 | Liposome Technology, Inc. | Polymer compound and coated particle composition |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5417978A (en) | 1993-07-29 | 1995-05-23 | Board Of Regents, The University Of Texas System | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
| NZ278490A (en) | 1993-12-09 | 1998-03-25 | Univ Jefferson | Chimeric polynucleotide with both ribo- and deoxyribonucleotides in one strand and deoxyribonucleotides in a second strand |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
| US5591721A (en) | 1994-10-25 | 1997-01-07 | Hybridon, Inc. | Method of down-regulating gene expression |
| US5512295A (en) | 1994-11-10 | 1996-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Synthetic liposomes for enhanced uptake and delivery |
| US5792747A (en) | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
| US5652356A (en) | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
| US20040266706A1 (en) * | 2002-11-05 | 2004-12-30 | Muthiah Manoharan | Cross-linked oligomeric compounds and their use in gene modulation |
| US6368855B1 (en) * | 1996-06-11 | 2002-04-09 | Antigen Express, Inc. | MHC class II antigen presenting cells containing oligonucleotides which inhibit Ii protein expression |
| AU4966997A (en) | 1996-11-18 | 1998-06-10 | Takeshi Imanishi | Novel nucleotide analogues |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6794499B2 (en) * | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| US20030096775A1 (en) * | 2001-10-23 | 2003-05-22 | Isis Pharmaceuticals Inc. | Antisense modulation of complement component C3 expression |
| US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| US6147200A (en) | 1999-08-19 | 2000-11-14 | Isis Pharmaceuticals, Inc. | 2'-O-acetamido modified monomers and oligomers |
| US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
| AU4819101A (en) * | 2000-04-13 | 2001-10-30 | University Of British Columbia, The | Modulating cell survival by modulating huntingtin function |
| WO2002027033A1 (en) * | 2000-09-29 | 2002-04-04 | Isis Pharmaceuticals, Inc. | Antisense modulation of mekk4 expression |
| US20050191638A1 (en) | 2002-02-20 | 2005-09-01 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
| EP1423537A4 (en) * | 2001-08-07 | 2006-11-29 | Univ Delaware | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING HUNTINGTON'S DISEASE |
| US20040096880A1 (en) * | 2001-08-07 | 2004-05-20 | Kmiec Eric B. | Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation |
| US7176303B2 (en) | 2003-11-06 | 2007-02-13 | Isis Pharmaceuticals, Inc. | Modulation of STAT5 expression |
| EP1478656B1 (en) * | 2002-02-01 | 2009-09-16 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
| US20050096284A1 (en) * | 2002-02-20 | 2005-05-05 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
| US20030232443A1 (en) * | 2002-06-18 | 2003-12-18 | Isis Pharmaceuticals Inc. | Antisense modulation of centromere protein B expression |
| US20040092465A1 (en) * | 2002-11-11 | 2004-05-13 | Isis Pharmaceuticals Inc. | Modulation of huntingtin interacting protein 1 expression |
| US20040102398A1 (en) * | 2002-11-23 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of B7H expression |
| US20080274989A1 (en) * | 2002-08-05 | 2008-11-06 | University Of Iowa Research Foundation | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof |
| US20050042646A1 (en) | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
| US20050106731A1 (en) | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
| US20050255086A1 (en) * | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
| WO2004027030A2 (en) | 2002-09-18 | 2004-04-01 | Isis Pharmaceuticals, Inc. | Efficient reduction of target rna’s by single- and double-stranded oligomeric compounds |
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| EP2213738B1 (en) * | 2002-11-14 | 2012-10-10 | Dharmacon, Inc. | siRNA molecules targeting Bcl-2 |
| US7250289B2 (en) * | 2002-11-20 | 2007-07-31 | Affymetrix, Inc. | Methods of genetic analysis of mouse |
| US7790867B2 (en) * | 2002-12-05 | 2010-09-07 | Rosetta Genomics Inc. | Vaccinia virus-related nucleic acids and microRNA |
| US20040191818A1 (en) * | 2003-02-26 | 2004-09-30 | O'toole Margot Mary | Compositions and methods for diagnosing and treating autoimmune diseases |
| CA2518475C (en) | 2003-03-07 | 2014-12-23 | Alnylam Pharmaceuticals, Inc. | Irna agents comprising asymmetrical modifications |
| WO2004101787A1 (ja) | 2003-05-14 | 2004-11-25 | Japan Science And Technology Agency | ハンチンチン遺伝子の発現抑制 |
| CA2532203A1 (en) * | 2003-07-14 | 2005-01-27 | Decode Genetics Ehf. | Method of diagnosis and treatment for asthma based on haplotype association |
| CA2533701A1 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| US7947658B2 (en) * | 2003-09-12 | 2011-05-24 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
| WO2005045032A2 (en) | 2003-10-20 | 2005-05-19 | Sima Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF EARLY GROWTH RESPONSE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US7341835B2 (en) * | 2004-01-13 | 2008-03-11 | Affymetrix, Inc. | Methods of analysis of alternative splicing in mouse |
| WO2005083436A1 (en) * | 2004-02-26 | 2005-09-09 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with integrin-linked kinase 1 (ilk1) |
| EP1735443A2 (en) * | 2004-04-14 | 2006-12-27 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US7374927B2 (en) * | 2004-05-03 | 2008-05-20 | Affymetrix, Inc. | Methods of analysis of degraded nucleic acid samples |
| KR20070085113A (ko) * | 2004-05-11 | 2007-08-27 | 가부시키가이샤 알파젠 | Rna간섭을 생기게 하는 폴리뉴클레오티드, 및 이를 이용한유전자발현억제 방법 |
| US7323308B2 (en) * | 2004-09-03 | 2008-01-29 | Affymetrix, Inc. | Methods of genetic analysis of E. coli |
| EP1891217A2 (en) | 2005-05-27 | 2008-02-27 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of stromal cell-derived factor-1 (sdf-1) gene expression using short interfering nucleic acid (sina) |
| DE202005008426U1 (de) | 2005-05-31 | 2005-09-15 | Ricon Sieb Und Foerdertechnik | Fördervorrichtung mit Fördertuch |
| AU2006279280A1 (en) | 2005-08-18 | 2007-02-22 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating neurological disease |
| EP1941059A4 (en) * | 2005-10-28 | 2010-11-03 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE HUNTINGTIN GENE |
| US8658608B2 (en) * | 2005-11-23 | 2014-02-25 | Yale University | Modified triple-helix forming oligonucleotides for targeted mutagenesis |
| WO2007089611A2 (en) | 2006-01-26 | 2007-08-09 | Isis Pharmaceuticals Inc. | Compositions and their uses directed to huntingtin |
| US7901882B2 (en) * | 2006-03-31 | 2011-03-08 | Affymetrix, Inc. | Analysis of methylation using nucleic acid arrays |
| US8076306B2 (en) | 2006-04-12 | 2011-12-13 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hepcidin |
| CA2662704A1 (en) | 2006-07-07 | 2008-01-10 | University Of Massachusetts | Rna silencing compositions and methods for the treatment of huntington's disease |
| EP2049664B1 (en) | 2006-08-11 | 2011-09-14 | Prosensa Technologies B.V. | Single stranded oligonucleotides complementary to repetitive elements for treating DNA repeat instability associated genetic disorders |
| US20080039415A1 (en) | 2006-08-11 | 2008-02-14 | Gregory Robert Stewart | Retrograde transport of sirna and therapeutic uses to treat neurologic disorders |
| EP2188298B1 (en) * | 2007-08-15 | 2013-09-18 | Isis Pharmaceuticals, Inc. | Tetrahydropyran nucleic acid analogs |
| EP2411505A4 (en) | 2009-03-26 | 2013-01-30 | Univ California | MESENCHYMAL STEM CELLS FOR PRODUCING HEMDERING RNA FOR SICKNESS MODIFICATION |
| US8957038B2 (en) | 2009-07-15 | 2015-02-17 | Medtronic, Inc. | Treatment of neurological disorders |
| US9574191B2 (en) | 2010-02-03 | 2017-02-21 | The Board Of Regents Of The University Of Texas System | Selective inhibition of polyglutamine protein expression |
| US10867398B2 (en) | 2017-11-21 | 2020-12-15 | Reliance Core Consulting LLC | Methods, systems, apparatuses and devices for facilitating motion analysis in an environment |
-
2007
- 2007-01-26 WO PCT/US2007/002215 patent/WO2007089611A2/en not_active Ceased
- 2007-01-26 US US11/627,916 patent/US7951934B2/en active Active
- 2007-01-26 PL PL09075505T patent/PL2161038T3/pl unknown
- 2007-01-26 PT PT90755059T patent/PT2161038E/pt unknown
- 2007-01-26 EP EP17151157.9A patent/EP3210633B1/en active Active
- 2007-01-26 EP EP07717061A patent/EP1991677A2/en not_active Withdrawn
- 2007-01-26 DK DK09075505.9T patent/DK2161038T3/da active
- 2007-01-26 EP EP10193685.4A patent/EP2428227B1/en active Active
- 2007-01-26 EP EP10193707.6A patent/EP2422819B1/en active Active
- 2007-01-26 EP EP09075505.9A patent/EP2161038B1/en active Active
- 2007-01-26 SI SI200731421T patent/SI2161038T1/sl unknown
- 2007-01-26 ES ES09075505.9T patent/ES2453380T3/es active Active
- 2007-01-26 AU AU2007210038A patent/AU2007210038B2/en active Active
- 2007-01-26 US US11/627,921 patent/US20070299027A1/en not_active Abandoned
- 2007-01-26 PL PL17151157T patent/PL3210633T3/pl unknown
- 2007-01-26 ES ES17151157T patent/ES2744098T3/es active Active
- 2007-01-26 WO PCT/US2007/002171 patent/WO2007089584A2/en not_active Ceased
- 2007-01-26 CA CA2638908A patent/CA2638908C/en active Active
- 2007-01-26 JP JP2008552447A patent/JP5425474B2/ja active Active
-
2009
- 2009-11-13 US US12/618,470 patent/US20100069472A1/en not_active Abandoned
-
2011
- 2011-04-19 US US13/090,146 patent/US8415465B2/en active Active
-
2012
- 2012-12-07 US US13/708,839 patent/US9057066B2/en active Active
-
2013
- 2013-03-07 US US13/789,368 patent/US8952145B2/en active Active
- 2013-04-10 AU AU2013203297A patent/AU2013203297B2/en active Active
- 2013-05-31 JP JP2013115737A patent/JP5916660B2/ja active Active
-
2015
- 2015-01-05 US US14/589,833 patent/US9353372B2/en active Active
- 2015-05-11 US US14/708,511 patent/US20160053256A1/en not_active Abandoned
- 2015-12-25 JP JP2015252875A patent/JP6395058B2/ja active Active
-
2016
- 2016-04-29 US US15/142,827 patent/US9920321B2/en active Active
-
2017
- 2017-07-12 AU AU2017204772A patent/AU2017204772B2/en active Active
- 2017-10-05 US US15/725,933 patent/US10738307B2/en active Active
-
2018
- 2018-02-07 US US15/891,154 patent/US10655129B2/en active Active
- 2018-03-28 JP JP2018061748A patent/JP2018117635A/ja active Pending
-
2019
- 2019-09-30 AU AU2019237389A patent/AU2019237389A1/en not_active Abandoned
-
2020
- 2020-02-14 JP JP2020023793A patent/JP2020096624A/ja active Pending
- 2020-04-15 US US16/848,968 patent/US11072794B2/en active Active
- 2020-08-10 US US16/988,862 patent/US20210017522A1/en active Pending
-
2021
- 2021-06-21 US US17/352,806 patent/US11761000B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016116520A5 (enExample) | ||
| JP2013226147A5 (enExample) | ||
| JP2020022483A5 (enExample) | ||
| JP2016530882A5 (enExample) | ||
| JP2016513976A5 (enExample) | ||
| JP2021505129A5 (enExample) | ||
| JP2014511686A5 (enExample) | ||
| JP2015507625A5 (enExample) | ||
| JP2020500929A5 (enExample) | ||
| JP2018512041A5 (enExample) | ||
| JP2016502858A5 (enExample) | ||
| JP2015523853A5 (enExample) | ||
| JP2018512110A5 (enExample) | ||
| HRP20191232T1 (hr) | Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina) | |
| EP4455285A3 (en) | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof | |
| JP2015519057A5 (enExample) | ||
| JP2016522674A5 (enExample) | ||
| JP2012505660A5 (enExample) | ||
| JP2015518712A5 (enExample) | ||
| HRP20201200T1 (hr) | OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK | |
| JP2015523854A5 (enExample) | ||
| JP2016521556A5 (enExample) | ||
| JP2017079759A5 (enExample) | ||
| JP2015523855A5 (enExample) | ||
| JP2016520310A5 (enExample) |